Why ResMed Inc.’s (RMD) Stock Is Down 7.25%
As of Friday, October 30, ResMed Inc.’s RMD share price has dipped by 7.25%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Commentary & Analysis
What You Need to Know About ResMed Inc.'s Q2 Earnings
ResMed Inc.'s fiscal Q2 earnings report was released on Thursday, October 29. Let's dive in to see if (RMD) missed or beat analyst's expectations.Rosalio Madrigal
Why ResMed Inc.’s (RMD) Stock Is Down 8.91%
As of Friday, August 07, ResMed Inc.’s RMD share price has dipped by 8.91%, which has investors questioning if this is right time to buy.Rosalio Madrigal
What You Need to Know About ResMed Inc.'s Q1 Earnings
ResMed Inc.'s fiscal Q1 earnings report was released on Thursday, August 06. Let's dive in to see if (RMD) missed or beat analyst's expectations.Michael Rose
Which Is a Better Investment, Glaukos Corporation or ResMed Inc. Stock?
Learn more about whether Glaukos Corporation or ResMed Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | RMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $32,764.7 | $402.2 | 91% |
|
| Shares Out (Mil) | 143.4 | 40.7 | 70% |
|
| Institutional Ownership | 99.4% | 83.6% | 88% |
|
| Float (Mil) | 139.8 | 35.5 | 67% |
|
| Beta | 0.75 | 0.85 | 43% |
|
| Avg Daily Volume (000s) | 1,444 | 312 | 76% |
|
| Price Change (52-week) |
(7.7%) | 63.0% | 44% |
|
| Growth | RMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.1% | 11.8% | 66% |
|
| Net Income (5yr) | 26.3% | (5.5%) | 81% |
|
| EPS (5yr) | 26.3% | 10.6% | 77 |
|
| Dividends (5yr) | 8.6% | 0.0% | 92% |
|
| Cash Flow (5yr) | 28.8% | (15.6%) | 85% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 20 | 20 | |
| Current EPS | $2.984 | $12.120 | $13.238 | |
| Month Ago EPS | $3.032 | $12.086 | $13.230 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $3.014 | $11.953 | $13.012 | |
| Year/Year Chg | 2.2% | 16.2% | 39.0% | |
| Financials | RMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5,733 | $141 | 76% |
|
| Net Income (TTM) (Mil) | $1,593 | ($9) | 90% |
|
| EPS (TTM) | $11.008 | ($0.400) | 95% |
|
| Operating Cash Flow (TTM) (Mil) | $1,771 | ($2) | 87% |
|
| Net Cash Flow (TTM) (Mil) | ($373) | $1 | 7% |
|
| Long-Term Debt (Q1) (Mil) | $419 | $27 | 57% |
|
| Enterprise Value (Q1) (Mil) | $31,943 | $381 | 88% |
|
| Valuation | RMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.51 | 2.55 | 82% |
|
| P/E | 21.2 | 28.4 | 55% |
|
| Dividend Yield | 1.1% | 0.0% | 68% |
|
| PEG (5yr hist) | 0.8 | 1.4 | 39% |
|
| Ratios | RMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.8% | 59.0% | 74% |
|
| Net Margin | 27.8% | (6.9%) | 86% |
|
| ROA | 19.3% | (11.3%) | 96% |
|
| ROE | 26.4% | (10.1%) | 85% |
|
| Liabilities to Assets | 27.6% | 47.1% | 19% |
|
| F-Score | 7 | 4 | 82% |
|
Passing Stock Screens
As of 11/2/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.8 |
FACTOR STRATEGY
Dividend (High Relative Yield) Screen
Factors: Yield, Value, Growth
Using the dividend-yield approach to invest during volatile markets.
| Performance Since Inception: | 9.0% |
| +/- S&P 500: | +1.6 |
